Plus Therapeutics Inc (PSTV)
NASDAQ · Healthcare
Plus Therapeutics Inc EBITDA 2009–2025
Plus Therapeutics Inc annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Plus Therapeutics Inc ebitda for the quarter ending March 31, 2026 was -7.0 M, a 107.17% increase year-over-year.
- Plus Therapeutics Inc ebitda for the twelve months ending March 31, 2026 was -15.3 M, a 57.71% decrease year-over-year.
- Plus Therapeutics Inc annual ebitda for 2025 was -14.9 M, a 7.45% increase from 2024.
- Plus Therapeutics Inc annual ebitda for 2024 was -13.8 M, a 8.90% increase from 2023.
- Plus Therapeutics Inc annual ebitda for 2023 was -12.7 M, a 87.82% increase from 2018.
- Plus Therapeutics Inc annual ebitda for 2018 was -6.8 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Plus Therapeutics Inc EBITDA — FAQ
Plus Therapeutics Inc (PSTV) ebitda over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see PSTV's ebitda history?
The chart and table above show Plus Therapeutics Inc's ebitda by year and by quarter, including the growth rate.